01.04.2023 | Tracker

Product Launch Tracker: HCPs are enthusiastic about the approval of two nasal sprays and an antifungal treatment.

By Alexandra Maria Chatziioannidou

Throughout March 2023 we tracked the global conversations of 2,254 eHCPs who posted 3,228 English-language Twitter posts about the launches and approvals of new products.

 

In March, several product approvals were discussed online by HCPs. They offered their thoughts on a novel treatment for Friedreich’s ataxia, approved migraine products, as well as opinions on Pfizer’s fourth doze booster COVID-19 vaccine.

One of the first approvals which generated significant conversation among HCPs was the FDA approval of Skylarys (omaveloxolone), as the first treatment for Friedreich’s ataxia. It is a rare genetic disease that damages the nervous system of the individual and impairs their muscle movement and speech. HCPs shared the approval news, with some seeing the approval as an important step forwards as the treatment is the only one to ever be approved for that specific disease. According to HCPs with this approval the FDA widens the path for rare disease treatments’ new approvals and quoted “we’ll be see many more therapies for neurological diseases in the near future”.

On the 14th of March an important COVID-19 update triggered the HCP online conversation. FDA approved Bivalent Pfizer-BioNTech COVID-19 vaccine as booster dose for certain children 6 months through 4 years old. This approval drew criticism from HCPs, as they mentioned that it is unnecessary for infants and “simply obscene”. Generally this FDA approval generated negative comments from HCPs and was compared with regulations from other countries.

Towards the end of the month, EMA recommends approval of Bimervax as a COVID-19 booster vaccine for people aged 16 years and above who have previously been vaccinated with mRNA COVID-19 vaccine. This approval was more neutrality discussed, as HCPs mainly shared the authorisation news. 

HCPs also shared their thoughts on FDA’s approval of fast-acting nasal spray spray to treat migraine under the name Zavzpret (zavegeoant) from Pfizer. It is the first nasal spray of CGRP inhibitors to be approved by the FDA for migraine treatment. HCPs were quick to share the approval news, where they posted optimistic reactions around it. HCPs congratulated the manufacturer and shared the trial results which were positive.

On March 22nd, the FDA approved a antifungal used for the treatment of Candidemia and invasive candidiasis called Rezzayo (rezafungin) by Cidara Therapeutics. Invasive candidiasis is a serious infection caused by a yeast (a type of fungus) called Candida that can affect the blood, heart, brain, eyes, bones, or other parts of the body. HCPs were enthusiastic about the approval as candidemia and invasive candidiasis had very limited therapy options, with the last medication having been approved more than a decade ago.

Emergent BioSolutions recently announced that the FDA has approved Narcan (naloxone) nasal spray for over the counter emergency treatment of opioid overdose. This medication has been characterised as life-saving and will be widely available without prescription. HCPs were enthusiastic about this approval as drug overdose persists as a major public health issue in the US. The nasal spray’s approval was described as “a step in the right direction” and a “historic milestone”.

The three most shared links from HCPs discussing product launches in March were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology

  • Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 March and 31 March 2023 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 March and 31 March 2023, there were 3,228 HCP mentions of new pharmaceutical product launches and drug approvals from 2,254 unique HCP authors from around the world. 

Click here to read the latest Product Launch Tracker

View all articles >

Meet the Author

Alexandra Maria Chatziioannidou

As a Biological Sciences graduate, Alexandra is passionate about making an impact in the healthcare industry through creating actionable insights and telling stories with data from online healthcare conversations.

Alexandra loves spending quality time with friends and family, both in the UK and back home in Greece, on her holidays. She also enjoys exploring new places!

Suggested next


24.08.2021 | Article

UK HCPs Debate The Comparisons Drawn Between COVID-19 And Other Viruses

UK HCPs Debate The Comparisons Drawn Between COVID-19 And Other Viruses

By Mark Sullivan

04.12.2020 | Article

What HCPs think about the 2020 NSCLC treatment landscape

What healthcare professionals think about Non-Small cell lung cancer treatment landscape

View all articles >